<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051904</url>
  </required_header>
  <id_info>
    <org_study_id>1160-0308</org_study_id>
    <nct_id>NCT05051904</nct_id>
  </id_info>
  <brief_title>A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin</brief_title>
  <official_title>Comparative Safety and Effectiveness of Warfarin, Dabigatran, and Rivaroxaban Among Japanese Patients With Non-valvular Atrial Fibrillation (NVAF) and Concomitant Coronary Artery Disease (CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the safety and effectiveness comparisons between warfarin,&#xD;
      dabigatran, and rivaroxaban in routine clinical practice among Japanese non-valvular atrial&#xD;
      fibrillation (NVAF) patients with concomitant coronary artery disease (CAD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2022</start_date>
  <completion_date type="Anticipated">April 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of fatal or non-fatal major bleeding (defined as any blood transfusion and/or any hospitalization with associated bleeding) in all three patient groups</measure>
    <time_frame>From April 2011 to December 2020, Up to 9 years and 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite outcome of stroke/Systemic Embolism/Myocardial Infarction/all-cause mortality (inpatient) /major bleeding/major Gastrointestinal bleeding (hospitalization due to GI bleeding)/Intracranial Hemorrhage in all three patient groups</measure>
    <time_frame>From April 2011 to December 2020, Up to 9 years and 8 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">17000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Warfarin users</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran users</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban users</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Japanese patients with non-valvular atrial fibrillation and concomitant coronary artery&#xD;
        disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -â‰¥18 years of age&#xD;
&#xD;
          -  Has one year of look-back period prior to the index date (defined as the first date of&#xD;
             prescription for dabigatran, rivaroxaban, or warfarin during the study period)&#xD;
&#xD;
          -  New users of warfarin, dabigatran, and rivaroxaban, defined as patients without&#xD;
             historic use of any oral anticoagulants during the look-back period&#xD;
&#xD;
          -  Has at least 1 diagnosis of NVAF during the look-back period prior to or on the index&#xD;
             date&#xD;
&#xD;
          -  Has at least 1 diagnosis of CAD during the look-back period prior to or on the index&#xD;
             date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with end-stage renal disease, or undergo hemodialysis, or experience&#xD;
             pregnancy during the study period&#xD;
&#xD;
          -  Initiate warfarin, dabigatran, rivaroxaban due to valvular Atrial Fibrillation (AF),&#xD;
             AF associated with mechanical valve malfunction or mechanical complication of heart&#xD;
             valve prosthesis, or rheumatic AF&#xD;
&#xD;
          -  Underwent joint replacement procedures or diagnosed with venous thromboembolism during&#xD;
             the look-back period prior to or on the index date&#xD;
&#xD;
          -  Prescribed with more than 1 oral anticoagulation (OAC) on the index date&#xD;
&#xD;
          -  Prescribed with more than 2 anti-platelet drugs per prescription (triple or quadruple&#xD;
             anti-platelet use), or prescribed with any anti-platelet injection&#xD;
&#xD;
          -  Patients with missing or ambiguous age or sex information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim - International GmbH</name>
      <address>
        <city>Ingelheim am Rhein</city>
        <zip>55216</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabrina de Souza Collas</last_name>
      <email>sabrina.de_souza_collas@boehringer-ingelheim.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

